QDENGA (TAK-003)

QDENGA (TAK-003) Latest News

The Drug Controller General of India (DCGI) recently granted market authorisation to Takeda Biopharmaceuticals India’s QDENGA (TAK-003), making it the first dengue vaccine to be approved in the country.

About QDENGA (TAK-003)

• It is a dengue vaccine developed by the Japanese pharmaceutical company Takeda.
• It is the first dengue vaccine to be approved in India.
• The vaccine has been approved for the prevention of dengue in individuals aged four to 60. 
• QDENGA is a live-attenuated (weakened) tetravalent vaccine designed to provide protection against all four dengue virus serotypes (DENV-1 to DENV-4).
• It is administered as a two-dose regimen, with doses given three months apart.
• The vaccine can be administered irrespective of whether an individual has had a previous dengue infection and does not require pre-vaccination screening.
• The vaccine has already been approved in more than 40 countries, including the European Union, the United Kingdom, Brazil, Indonesia, and Argentina. 

 What is Dengue?

• Dengue disease is a mosquito-borne tropical disease caused by the dengue virus, leading to mild, flu-like symptoms in most people.
• However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage.
• It poses a significant global public health threat, with prevalence in over 125 countries.
• India accounts for nearly one-third of the global dengue burden.

Source: TH

‹ ›